137 related articles for article (PubMed ID: 8618956)
1. Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia.
Brooks RR; Carpenter JF; Miller KE; Maynard AE
Proc Soc Exp Biol Med; 1996 May; 212(1):84-93. PubMed ID: 8618956
[TBL] [Abstract][Full Text] [Related]
2. Effects of azimilide and d,l-sotalol on the heart rate and blood pressure response to isoproterenol in anesthetized rats.
Mittelstadt SW; Maynard AE; Benn DR; Lowe ER; Kostreva DR
Cardiovasc Drugs Ther; 1997 Sep; 11(4):591-8. PubMed ID: 9358964
[TBL] [Abstract][Full Text] [Related]
3. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
Drexler AP; Micklas JM; Brooks RR
J Cardiovasc Pharmacol; 1996 Dec; 28(6):848-55. PubMed ID: 8961084
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of isoproterenol-induced tachycardia by azimilide in the isolated perfused guinea pig heart.
Miller KE; Carpenter JF; Brooks RR
Cardiovasc Drugs Ther; 1998 Mar; 12(1):83-91. PubMed ID: 9607136
[TBL] [Abstract][Full Text] [Related]
5. Broad sensitivity of rodent arrhythmia models to class I, II, III, and IV antiarrhythmic agents.
Brooks RR; Miller KE; Carpenter JF; Jones SM
Proc Soc Exp Biol Med; 1989 Jun; 191(2):201-9. PubMed ID: 2726785
[TBL] [Abstract][Full Text] [Related]
6. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties.
Nattel S; Liu L; St-Georges D
Cardiovasc Res; 1998 Mar; 37(3):627-35. PubMed ID: 9659446
[TBL] [Abstract][Full Text] [Related]
7. Azimilide dihydrochloride: a unique class III antiarrhythmic agent.
Tran HT
Heart Dis; 1999; 1(2):114-6. PubMed ID: 11720612
[TBL] [Abstract][Full Text] [Related]
8. Azimilide dihydrochloride, a novel antiarrhythmic agent.
Karam R; Marcello S; Brooks RR; Corey AE; Moore A
Am J Cardiol; 1998 Mar; 81(6A):40D-46D. PubMed ID: 9537222
[TBL] [Abstract][Full Text] [Related]
9. The azimilide post-infarct survival evaluation (ALIVE) trial.
Camm AJ; Karam R; Pratt CM
Am J Cardiol; 1998 Mar; 81(6A):35D-39D. PubMed ID: 9537221
[TBL] [Abstract][Full Text] [Related]
10. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators.
Pritchett EL; Page RL; Connolly SJ; Marcello SR; Schnell DJ; Wilkinson WE
J Am Coll Cardiol; 2000 Sep; 36(3):794-802. PubMed ID: 10987602
[TBL] [Abstract][Full Text] [Related]
11. Effects of azimilide, a KV(r) and KV(s) blocker, on canine ventricular arrhythmia models.
Xue Y; Yamada C; Chino D; Hashimoto K
Eur J Pharmacol; 1999 Jul; 376(1-2):27-35. PubMed ID: 10440086
[TBL] [Abstract][Full Text] [Related]
12. Effects of intravenous azimilide on cardiac performance, fibrillation threshold, and hemodynamics in anesthetized dogs.
Brooks RR; Finch SL
Arzneimittelforschung; 2000 Jul; 50(7):597-605. PubMed ID: 10965415
[TBL] [Abstract][Full Text] [Related]
13. Azimilide.
Clemett D; Markham A
Drugs; 2000 Feb; 59(2):271-7; discussion 278-9. PubMed ID: 10730550
[TBL] [Abstract][Full Text] [Related]
14. Electrophysiological effects of azimilide in an in vitro model of simulated-ischemia and reperfusion in guinea-pig ventricular myocardium.
Ducroq J; Rouet R; Puddu PE; Sallé L; Tabourel C; Ducouret P; Gérard JL
Eur J Pharmacol; 2005 Aug; 518(2-3):165-74. PubMed ID: 16083874
[TBL] [Abstract][Full Text] [Related]
15. Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation.
Qi XQ; Newman D; Dorian P
J Interv Card Electrophysiol; 1999 Mar; 3(1):61-7. PubMed ID: 10354978
[TBL] [Abstract][Full Text] [Related]
16. Azimilide for atrial fibrillation: clinical trial results and implications.
Pritchett EL; Marcello SR
Card Electrophysiol Rev; 2003 Sep; 7(3):215-9. PubMed ID: 14739716
[TBL] [Abstract][Full Text] [Related]
17. Azimilide dihydrochloride: a new class III anti-arrhythmic agent.
Abrol R; Page RL
Expert Opin Investig Drugs; 2000 Nov; 9(11):2705-15. PubMed ID: 11060832
[TBL] [Abstract][Full Text] [Related]
18. The class III effect of azimilide is not associated with reverse use-dependence in open-chest dogs.
Qi XQ; Newman D; Dorian P
J Cardiovasc Pharmacol; 1999 Dec; 34(6):898-903. PubMed ID: 10598136
[TBL] [Abstract][Full Text] [Related]
19. Effects of azimilide, a new class III antiarrhythmic drug, on reentrant circuits causing ventricular tachycardia and fibrillation in a canine model of myocardial infarction.
Schmitt H; Cabo C; Coromilas JC; Wit AL
J Cardiovasc Electrophysiol; 2001 Sep; 12(9):1025-33. PubMed ID: 11573692
[TBL] [Abstract][Full Text] [Related]
20. Effects of AH-1058, a new antiarrhythmic drug, on experimental arrhythmias and cardiac membrane currents.
Takahara A; Uneyama H; Sasaki N; Ueda H; Dohmoto H; Shoji M; Hara Y; Nakaya H; Yoshimoto R
J Cardiovasc Pharmacol; 1999 Apr; 33(4):625-32. PubMed ID: 10218734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
